|
|
|
|
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
| Item 2.02. |
Results of Operations and Financial Condition.
|
| Item 7.01. |
Regulation FD Disclosure.
|
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits
|
|
Press Release dated August 2, 2023
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
TURNING POINT BRANDS, INC.
|
|||
|
Dated: August 2, 2023
|
By:
|
/s/ Brittani N. Cushman
|
|
|
Brittani N. Cushman
|
|||
|
Senior Vice President, General Counsel and Secretary
|
|||
| • |
Total consolidated net sales increased 2.6% to $105.6 million
|
| o |
Zig-Zag Products net sales increased by 1.1%
|
| o |
Stoker’s Products net sales increased by 7.3%
|
| o |
Creative Distribution Solutions net sales decreased by 1.3%
|
| • |
Gross profit increased 2.0% to $52.5 million
|
| • |
Net income increased 83.0% to $9.9 million
|
| • |
Adjusted net income increased 8.4% to $15.3 million (see Schedule B for a reconciliation to net income)
|
| • |
Adjusted EBITDA increased 2.2% to $25.3 million (see Schedule A for a reconciliation to net income)
|
| • |
Diluted EPS of $0.53 and Adjusted Diluted EPS of $0.79 compared to $0.30 and $0.70 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)
|
| • |
$0.1 million of ERP / CRM duplicative system costs compared to $0.9 million of ERP / CRP scoping expenses in the previous year
|
| • |
$2.1 million of stock options, restricted stock and incentive expense compared to $1.5 million in the year-ago period
|
| • |
$0.7 million of FDA PMTA-related expenses for modern oral products compared to $2.0 million in the year-ago period
|
| • |
$0.1 million of transaction expenses compared to $0.4 million in the year-ago period
|
| • |
$0.0 million of restructuring costs as compared to $0.3 million in the year-ago period
|
|
Three Months Ended June 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Net sales
|
$
|
105,595
|
$
|
102,925
|
||||
|
Cost of sales
|
53,117
|
51,456
|
||||||
|
Gross profit
|
52,478
|
51,469
|
||||||
|
Selling, general, and administrative expenses
|
31,933
|
33,323
|
||||||
|
Operating income
|
20,545
|
18,146
|
||||||
|
Interest expense, net
|
4,019
|
5,144
|
||||||
|
Investment loss
|
4,080
|
6,227
|
||||||
|
Gain on extinguishment of debt
|
(600
|
)
|
-
|
|||||
|
Income before income taxes
|
13,046
|
6,775
|
||||||
|
Income tax expense
|
3,338
|
1,569
|
||||||
|
Consolidated net income
|
9,708
|
5,206
|
||||||
|
Net loss attributable to non-controlling interest
|
(217
|
)
|
(218
|
)
|
||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
9,925
|
$
|
5,424
|
||||
|
Basic income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.56
|
$
|
0.30
|
||||
|
Diluted income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.53
|
$
|
0.30
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
17,584,241
|
18,063,259
|
||||||
|
Diluted
|
20,409,943
|
21,443,279
|
||||||
|
Supplemental disclosures of statements of income information:
|
||||||||
|
Excise tax expense
|
$
|
5,407
|
$
|
6,141
|
||||
|
FDA fees
|
$
|
116
|
$
|
171
|
||||
|
(unaudited)
|
||||||||
|
June 30,
|
December 31,
|
|||||||
|
ASSETS
|
2023
|
2022
|
||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
100,507
|
$
|
106,403
|
||||
|
Accounts receivable, net of allowances of $103 in 2023 and $114 in 2022
|
7,920
|
8,377
|
||||||
|
Inventories
|
125,056
|
119,915
|
||||||
|
Other current assets
|
18,216
|
22,959
|
||||||
|
Total current assets
|
251,699
|
257,654
|
||||||
|
Property, plant, and equipment, net
|
24,128
|
22,788
|
||||||
|
Deferred income taxes
|
7,966
|
8,443
|
||||||
|
Right of use assets
|
10,923
|
12,465
|
||||||
|
Deferred financing costs, net
|
229
|
282
|
||||||
|
Goodwill
|
136,244
|
136,253
|
||||||
|
Other intangible assets, net
|
82,048
|
83,592
|
||||||
|
Master Settlement Agreement (MSA) escrow deposits
|
28,229
|
27,980
|
||||||
|
Other assets
|
18,208
|
22,649
|
||||||
|
Total assets
|
$
|
559,674
|
$
|
572,106
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
10,802
|
$
|
8,355
|
||||
|
Accrued liabilities
|
30,898
|
33,001
|
||||||
|
Other current liabilities
|
5
|
20
|
||||||
|
Total current liabilities
|
41,705
|
41,376
|
||||||
|
Notes payable and long-term debt
|
379,195
|
406,757
|
||||||
|
Lease liabilities
|
9,528
|
10,593
|
||||||
|
Total liabilities
|
430,428
|
458,726
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
|
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,912,039 issued shares and 17,595,579 outstanding shares at June 30,
2023, and 19,801,623 issued shares and 17,485,163 outstanding shares at December 31, 2022
|
199
|
198
|
||||||
|
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
|
Additional paid-in capital
|
115,272
|
113,242
|
||||||
|
Cost of repurchased common stock (2,316,460 shares at June 30, 2023 and December 31, 2022)
|
(78,093
|
)
|
(78,093
|
)
|
||||
|
Accumulated other comprehensive loss
|
(3,181
|
)
|
(2,393
|
)
|
||||
|
Accumulated earnings
|
93,873
|
78,691
|
||||||
|
Non-controlling interest
|
1,176
|
1,735
|
||||||
|
Total stockholders' equity
|
129,246
|
113,380
|
||||||
|
Total liabilities and stockholders' equity
|
$
|
559,674
|
$
|
572,106
|
||||
|
Six Months Ended June 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Consolidated net income
|
$
|
17,050
|
$
|
15,977
|
||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Gain on extinguishment of debt
|
(1,377
|
)
|
-
|
|||||
|
Loss (gain) on sale of property, plant, and equipment
|
44
|
(8
|
)
|
|||||
|
Depreciation expense
|
1,535
|
1,750
|
||||||
|
Amortization of other intangible assets
|
1,542
|
919
|
||||||
|
Amortization of deferred financing costs
|
1,225
|
1,291
|
||||||
|
Deferred income tax expense (benefit)
|
659
|
(146
|
)
|
|||||
|
Stock compensation expense
|
2,836
|
2,661
|
||||||
|
Noncash lease income
|
(29
|
)
|
(6
|
)
|
||||
|
Loss on investments
|
8,989
|
6,258
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
456
|
(2,673
|
)
|
|||||
|
Inventories
|
(5,146
|
)
|
(27,499
|
)
|
||||
|
Other current assets
|
3,769
|
(598
|
)
|
|||||
|
Other assets
|
(4,548
|
)
|
624
|
|||||
|
Accounts payable
|
2,500
|
7,240
|
||||||
|
Accrued liabilities and other
|
(1,972
|
)
|
1,359
|
|||||
|
Net cash provided by operating activities
|
$
|
27,533
|
$
|
7,149
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Capital expenditures
|
$
|
(2,993
|
)
|
$
|
(5,694
|
)
|
||
|
Restricted cash, MSA escrow deposits
|
-
|
(10,078
|
)
|
|||||
|
Proceeds on the sale of property, plant and equipment
|
3
|
63
|
||||||
|
Net cash used in investing activities
|
$
|
(2,990
|
)
|
$
|
(15,709
|
)
|
||
|
Cash flows from financing activities:
|
||||||||
|
Repurchased Convertible Senior Notes
|
$
|
(27,357
|
)
|
$
|
-
|
|||
|
Proceeds from call options
|
70
|
-
|
||||||
|
Payment of dividends
|
(2,209
|
)
|
(2,181
|
)
|
||||
|
Exercise of options
|
406
|
475
|
||||||
|
Redemption of options
|
(346
|
)
|
(155
|
)
|
||||
|
Redemption of performance restricted stock units
|
(995
|
)
|
(1,228
|
)
|
||||
|
Common stock repurchased
|
-
|
(19,418
|
)
|
|||||
|
Net cash used in financing activities
|
$
|
(30,431
|
)
|
$
|
(22,507
|
)
|
||
|
Net decrease in cash
|
$
|
(5,888
|
)
|
$
|
(31,067
|
)
|
||
|
Effect of foreign currency translation on cash
|
$
|
(8
|
)
|
$
|
56
|
|||
|
Cash, beginning of period:
|
||||||||
|
Unrestricted
|
106,403
|
128,320
|
||||||
|
Restricted
|
4,929
|
15,155
|
||||||
|
Total cash at beginning of period
|
111,332
|
143,475
|
||||||
|
Cash, end of period:
|
||||||||
|
Unrestricted
|
100,507
|
107,429
|
||||||
|
Restricted
|
4,929
|
5,035
|
||||||
|
Total cash at end of period
|
$
|
105,436
|
$
|
112,464
|
||||
|
Three Months Ended
June 30,
|
||||||||
|
2023
|
2022
|
|||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
9,925
|
$
|
5,424
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
4,019
|
5,144
|
||||||
|
Gain on extinguishment of debt
|
(600
|
)
|
-
|
|||||
|
Income tax expense
|
3,338
|
1,569
|
||||||
|
Depreciation expense
|
759
|
879
|
||||||
|
Amortization expense
|
771
|
456
|
||||||
|
EBITDA
|
$
|
18,212
|
$
|
13,472
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Corporate restructuring (a)
|
-
|
270
|
||||||
|
ERP/CRM (b)
|
138
|
861
|
||||||
|
Stock options, restricted stock, and incentives expense (c)
|
2,093
|
1,502
|
||||||
|
Transactional expenses (d)
|
82
|
364
|
||||||
|
FDA PMTA (e)
|
662
|
1,957
|
||||||
|
Non-cash asset impairment (f)
|
4,092
|
6,300
|
||||||
|
Adjusted EBITDA
|
$
|
25,279
|
$
|
24,726
|
||||
|
(a)
|
Represents costs associated with corporate restructuring, including severance.
|
|
(b)
|
Represents cost assosicated with scoping and mobilization of new ERP and CRM systems and cost of duplicative
ERP licenses.
|
|
(c)
|
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units
("PRSUs").
|
|
(d)
|
Represents the fees incurred for transaction expenses.
|
|
(e)
|
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
|
(f)
|
Represents impairment of investment assets.
|
|
(unaudited)
|
Three Months Ended
|
Three Months Ended
|
||||||||||||||
|
June 30, 2023
|
June 30, 2022
|
|||||||||||||||
| |
Net Income
|
Diluted EPS
|
Net Income
|
Diluted EPS
|
||||||||||||
|
GAAP EPS
|
$
|
9,925
|
$
|
0.53
|
$
|
5,424
|
$
|
0.30
|
||||||||
|
Gain on extinguishment of debt (a)
|
(446
|
)
|
(0.02
|
)
|
-
|
-
|
||||||||||
|
Corporate restructuring (b)
|
-
|
-
|
207
|
0.01
|
||||||||||||
|
ERP/CRM (c)
|
103
|
0.01
|
662
|
0.03
|
||||||||||||
|
Stock options, restricted stock, and incentives expense (d)
|
1,557
|
0.08
|
1,154
|
0.05
|
||||||||||||
|
Transactional expenses (e)
|
61
|
0.00
|
280
|
0.01
|
||||||||||||
|
FDA PMTA (f)
|
493
|
0.02
|
1,504
|
0.07
|
||||||||||||
|
Non-cash asset impairment (g)
|
3,045
|
0.15
|
4,841
|
0.23
|
||||||||||||
|
Tax (expense) benefit (h)
|
560
|
0.03
|
35
|
0.00
|
||||||||||||
|
Adjusted
|
$
|
15,297
|
$
|
0.79
|
$
|
14,106
|
$
|
0.70
|
||||||||
|
(a)
|
Represents gain on extinguishment of debt tax effected at the quarterly tax rate.
|
|
(b)
|
Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate.
|
|
(c)
|
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at
the quarterly tax rate.
|
|
(d)
|
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.
|
|
(e)
|
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.
|
|
(f)
|
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.
|
|
(g)
|
Represents impairment of investment assets tax effected at the quarterly tax rate.
|
|
(h)
|
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2023 and 2022.
|
|
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
Creative Distribution Solutions
|
||||||||||||||||||||||||||||
|
|
2nd Quarter
|
2nd Quarter
|
2nd Quarter
|
2nd Quarter
|
2nd Quarter
|
2nd Quarter
|
2nd Quarter
|
2nd Quarter
|
||||||||||||||||||||||||
|
|
2023
|
2022
|
2023
|
2022
|
2023
|
2022
|
2023
|
2022
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
|
Net sales
|
$
|
105,595
|
$
|
102,925
|
$
|
46,722
|
$
|
46,226
|
$
|
36,056
|
$
|
33,588
|
$
|
22,817
|
$
|
23,111
|
||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
|
Gross profit
|
$
|
52,478
|
$
|
51,469
|
$
|
26,422
|
$
|
26,430
|
$
|
19,968
|
$
|
18,079
|
$
|
6,088
|
$
|
6,960
|
||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
|
Operating income
|
$
|
20,545
|
$
|
18,146
|
$
|
17,000
|
$
|
18,503
|
$
|
15,110
|
$
|
13,378
|
$
|
460
|
$
|
552
|
||||||||||||||||
|
Adjustments:
|
||||||||||||||||||||||||||||||||
|
Corporate restructuring
|
-
|
270
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
ERP/CRM
|
138
|
861
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Transactional expenses
|
82
|
364
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
FDA PMTA
|
662
|
1,957
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Adjusted operating income
|
$
|
21,427
|
$
|
21,598
|
$
|
17,000
|
$
|
18,503
|
$
|
15,110
|
$
|
13,378
|
$
|
460
|
$
|
552
|
||||||||||||||||
| 10 |
|
Turning Point Brands, Inc. | www.turningpointbrands.com | [email protected] | 502.774.9238
|